California-based Renasant Bio announced its launch to advance next-generation disease-modifying treatments for autosomal ...

Nuclidium, a radiopharma company developing a proprietary copper-based theranostic platform, has announced the successful ...

Sino-American drug discovery firms TandemAI and Perpetual Medicines have merged.

BrainXell, a US biotechnology company developing iPSC-based CNS disease models and regenerative cell therapies, has announced ...

Shares in US biotech Ultragenyx Pharmaceutical (Nasdaq: RARE) and its UK-based partner Mereo BioPharma (Nasdaq: MREO) tumbled ...

Chinese cell therapy developer NK CellTech has raised nearly 100 million renminbi ($14 million) in an extended series A+++ ...

Sino-American biopharma Ascentage Pharma announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575 ...

Lewy body dementia (LBD) remains one of the most overlooked and complex neurodegenerative conditions, but momentum is ...

The US Food and Drug Administration (FDA) has approved US mRNA specialist Moderna supplemental Biologics License Application ...

French biotech Osivax has published results from a Phase IIa trial showing that its lead candidate OVX836, a broad-spectrum ...

China-based biotech Biocytogen has signed a global licensing agreement with oncology-focused BeOne Medicines (SHA: 688235), ...

The US Food and Drug Administration (FDA) has accepted for review Merck & Co’s New Drug Application (NDA) for ...